Drug
Lacosamide
Lacosamide: highest development phase Post-Market, developed by UCB. 6 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lacosamide NCT01190098 | Post-Market | Partial Epilepsy |
| Lacosamide NCT02124564 | Phase 3 | Epilepsy |
| lacosamide NCT00522275 | Phase 3 | Partial Epilepsies |
| Lacosamide NCT00938431 | Phase 2 | Epilepsy |
| Lacosamide NCT00938912 | Phase 2 | Epilepsy |
| Lacosamide tablet NCT01796938 | Phase 1 | Healthy |
Latest
No recent events.
Follow Lacosamide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.